Gilead nears deal to buy Immunomedics for more than $20 billion: Report

A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer called Metastatic Triple-Negative Breast Cancer, could be announced Monday if not sooner, the Wall Street Journal said, citing people familiar with the matter.

https://ift.tt/33mPbim